Moscow-Sana
The Russian Federal Biomedical Agency announced that the drug "Covid Globulin", the first registered immune drug in the world, is currently undergoing clinical trials.
Russia Today website quoted Olga Eichler, head of the Agency’s Medical Support Department, as saying today on the sidelines of the East Economic Forum, “The first phase of clinical trials for a drug prepared in the laboratory of the Rostec Corporation’s Immunoglobulin Natesymbio, which is a distinct immunoglobulin against Covid, is underway.”
In early April, the Russian Ministry of Health registered the world's first distinct immunoglobulin for the Corona virus on the basis of the blood plasma of people recovering from the disease. After the completion of the second and third phases of clinical trials, the drug is expected to be used in the treatment of moderate and severe cases of Covid-19 infection.